Board Seeks Shareholder Approval for Substantial Capital Range and Equity Plan Increases, Potentially Diluting Existing Shares by Over 70%

summarizeSummary

ADC Therapeutics SA is proposing to significantly increase its authorized share capital and equity incentive plan shares, which could lead to over 70% dilution for current shareholders, citing ongoing losses and the need for future funding.

check_boxKey Events

• Proposed Increase in Equity Incentive Plan Shares

  Shareholders will vote on increasing the number of shares authorized under the 2019 Equity Incentive Plan by 7,700,000 shares.

• Expanded Conditional Share Capital for Employee Participation

  The company proposes to increase the conditional share capital for employee participation (Article 4b) by 6,948,624 shares, from 9,887,629 to 16,836,253 common shares.

• Increased Conditional Share Capital for Financing and Acquisitions

  A proposal seeks to increase the conditional share capital for financing, acquisitions, and other purposes (Article 4c) by 10,000,000 shares, from 38,026,929 to 48,026,929 common shares.

• Introduction of New Conditional Share Capital Based on Capital Range

  The board proposes to introduce a new conditional share capital (Article 4d) of up to 64,863,182 common shares, which operates within the overall capital range (Article 4a).

auto_awesomeAnalysis

ADC Therapeutics SA is seeking shareholder approval for several proposals that, if fully utilized, could significantly dilute existing shareholders. The company, which reported a net loss of $142.6 million for 2025 and anticipates continued losses, explicitly states the need for additional capital to fund operations and execute its business plan. The proposed increases in authorized shares across various plans and capital ranges represent a substantial potential for future equity raises. Furthermore, the filing acknowledges that these proposals could have anti-takeover effects, which may impact corporate control dynamics.